New combo aims to supercharge standard thyroid cancer therapy
NCT ID NCT05783323
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether giving larotrectinib for 6 months can make thyroid cancer cells more responsive to radioactive iodine therapy. It enrolls 13 children and young adults with a specific genetic change (NTRK fusion) whose cancer has spread to the lungs. The goal is to see if more patients achieve complete shrinkage of lung tumors compared to standard treatment alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Larotrectinib (a targeted cancer drug) and radioactive iodine (131I)
What this could lead to
If it works, this could make radioactive iodine therapy more effective for people with a specific type of thyroid cancer, potentially reducing the need for stronger treatments.
What could go wrong
This is a small, early-phase trial with only 13 participants, so results may not apply to everyone. Larotrectinib and radioactive iodine can have side effects, and the combination may not improve outcomes as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Seattle Children's Hospital
RECRUITINGSeattle, Washington, 98105, United States
Contact
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 19807, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94115, United States
Contact Email: •••••@•••••